HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells

Journal of Human Virology

Volumn 2, Issue 5, 1999, Pages 261-269

  Weichold, Frank F ^a   Bryant, Joseph L ^a   Pati, Shibani ^a   Barabitskaya, Oxana ^a   Gallo, Robert C ^a   Reitz Jr , Marvin S ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Apoptosis TNF; Chronic infection; Fas ligand; Immune activation

Indexed keywords

PROTEINASE INHIBITOR; RITONAVIR;

ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS CELL INTERACTION;

ANNEXIN A5; ANTIGENS, CD95; APOPTOSIS; CASPASE 1; CASPASE 3; CASPASES; CELL SURVIVAL; FAS LIGAND PROTEIN; HIV PROTEASE INHIBITORS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIGANDS; MEMBRANE GLYCOPROTEINS; RITONAVIR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033504073     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. + cell counts despite persistently detectable HIV load. N Engl J Med 1998;338: 1074.
2. Johnson N, Parkin JM. Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis. Clin Exp Immunol 1998;113:229.
3. Cohen J. AIDS therapy: failure isn't what it used to be . . . but neither is success [news]. Science 1998;279: 1133.
4. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science 1998;280:1871.
5. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998;178:70.
6. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997;32:194.
7. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456.
8. Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F. Programmed death of T cells in HIV-1 infection. Science 1992;257:217.
9. + T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992;175: 331.
10. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305.
11. + lymphocyte depletion and human immunodeficiency virus replication. Blood 1997;89:1357.
12. Sloand EM, Maciejewski JP, Sato T, et al. The role of interleukin-converting enzyme in Fas-mediated apoptosis in HIV-1 infection. J Clin Invest 1998;101:195.
13. Debatin KM, Fahrig-Faissner A, Enenkel-Stoodt S, Kreuz W, Benner A, Krammer PH. High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children [letter]. Blood 1994;83:3101.
14. Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanaraman VS, Pahwa S. Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood 1993;82:3392.
15. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995;181:2029.
16. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998;102:79.
17. Bohler T, Herr I, Debatin KM, Geiss M, Haas J. Down-regulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy [letter; comment]. Blood 1997;90:886.
18. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338:1281.
19. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;173:321.
20. + T cell homeostasis and function in advanced HIV disease [see comments]. Science 1997;277:112.
21. Plana M, Garcia F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study [letter]. Lancet 1998;352:1194.
22. Margolin N, Raybuck SA, Wilson KP, et al. Substrate and inhibitor specificity of interleukin-1 beta-converting enzyme and related caspases. J Biol Chem 1997;272: 7223.
23. Alden C, Sanderson T, Morris D, Ivett J, Baron D, Snook S. "Have you seen this?" Protease inhibitor toxicity. Toxicol Pathol 1997;25:113.
24. Wang KK, Posmantur R, Nath R, et al. Simultaneous degradation of alphaII-and betall-spectrin by caspase 3 (CPP32) in apoptotic cells. J Biol Chem 1998;273:22490.
25. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011.
26. Pope M, Betjes MG, Romani N, et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 1994;78:389.
27. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol 1996;70:199.
28. + T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J Immunol 1997;158: 2456.
29. Wu MX, Daley JF, Rasmussen RA, Schlossman SF. Monocytes are required to prime peripheral blood T cells to undergo apoptosis. Proc Natl Acad Sci USA 1995;92: 1525.
30. Munn DH, Pressey J, Beall AC, Hudes R, Alderson MR. Selective activation-induced apoptosis of peripheral T cells imposed by macrophages: a potential mechanism of antigen-specific peripheral lymphocyte deletion. J Immunol 1996;156:523.
31. Norvir, Ritonavir Product Monograph [package insert]. North Chicago, IL: Abbott Laboratories, 1997.
32. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484.
33. Maciejewski JP, Weichold FF, Young NS. HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-alpha. J Immunol 1994;153:4303.
34. Zella D, Barabitskaja O, Burns JM, et al. Interferon-gamma increases expression of chemokine receptors CCR1, CCR3, and CCR5, but not CXCR4 in monocytoid U937 cells. Blood 1998;91:4444.
35. Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S. Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor-alpha secretion. Blood 1994;84:2622.
36. Bottcher M, Grosse F. HIV-1 protease inhibits its homologous reverse transcriptase by protein-protein interaction. Nucleic Acids Res 1997;25:1709.
37. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231.
38. Andre P, Groettrup M, Klenerman P, et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998;95:13120.
39. Kobayashi N, Hamamoto Y, Yamamoto N, Ishii A, Yonehara M, Yonehara S. Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication. Proc Natl Acad Sci USA 1990;87:9620.
40. Sarin A, Clerici M, Blatt SP, Hendrix CW, Shearer GM, Henkart PA. Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. J Immunol 1994;153:862.
41. Chinnaiyan AM, Woffendin C, Dixit VM, Nabel GJ. The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nat Med 1997;3:333.
42. Clouston WM, Kerr JF. Apoptosis, lymphocytotoxicity and the containment of viral infections. Med Hypotheses 1985;18:399.
43. Clem RJ, Miller LK. Apoptosis reduces both the in vitro replication and the in vivo infectivity of a baculovirus. J Virol 1993;67:3730.
44. + T cells by a Fas-independent mechanism. J Exp Med 1998;187:1113.
45. Kolesnitchenko V, King L, Riva A, Tani Y, Korsmeyer SJ, Cohen DI. A major human immunodeficiency virus type 1-initiated killing pathway distinct from apoptosis. J Virol 1997;71:9753.
46. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 infected humans. Nat Med 1999;5:83.